BRIDGEWATER, N.J., Oct. 19, 2016 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (OTCQB:VLRX) announced today that it has reached the commercial milestone of the 10 millionth V-Go® device dispensed. V-Go, the wearable, discreet and easy-to-use alternative to multiple daily insulin injections with pens and syringes, has demonstrated clinical effectiveness by lowering A1C levels in patients with diabetes, and has done so at lower prescribed insulin dosages and similar costs to payors and patients with diabetes1.
John Timberlake, President and Chief Executive Officer of Valeritas commented, “This exciting milestone of 10 million V-Go devices, or the equivalent of 28,000 patients on therapy every day for a year, is a testament to the clinical value and patient acceptance that we continue to see, and a strong signal that both prescribers and patients with diabetes view V-Go as a valuable alternative to multiple daily injections with insulin pens and syringes. We look forward to advancing our mission in helping patients with Type 2 Diabetes better control their blood glucose and improve their quality of life.”
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company focused on developing innovative technologies to improve the health and quality of life of people with Type 2 diabetes. Valeritas’ flagship product, V-Go® Disposable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery solution for patients with Type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in a state-of-the-art facility in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.
Forward Looking Statements
This press release may contain forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Valeritas technologies, business and product development plans and market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue Valeritas’ business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the V-Go® Disposable Insulin Delivery device with limited resources, competition in the industry in which Valeritas operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and Valeritas assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Valeritas files with the SEC available at www.sec.gov.
1 Clinical and Cost-Effectiveness of Insulin Delivery with V-Go® Disposable Insulin Delivery Device Versus Multiple Daily Injections in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin. Lajara R, Davidson JA, Nikkel CC, Morris TL. Endocr Pract. 2016 Jun;22(6):726-35.
Investor Contacts: Nick Laudico / Robert Flamm, Ph.D. The Ruth Group (646)536-7030 / 7017 IR@valeritas.com Or The Del Mar Consulting Group, Inc. Robert B. Prag, President 858-794-9500 firstname.lastname@example.org Media Contact: Christopher Hippolyte The Ruth Group (646)536-7023 PR@valeritas.com